ViAqua
2014
- Shai Ufaz, PhD, Co-Founder and CEO
Haifa, Israel
- Increased demand for healthier and sustainable seafood Jump to footnote 1
- Increased uptake of solutions, products, and technologies that enhance productivity of blue economy Jump to footnote 2
The company was established to address the growing need for effective, specific, and affordable health management of diseases in aquaculture. ViAqua’s biotechnology-based, oral delivery platform is intended for targeted administration of nucleic acid-based therapeutics. ViAqua’s first product is an RNA-based solution for application against the White Spot Shrimp Virus (WSSV) pandemic.
Insights
News
Footnotes
S2G North Star Interim Outcomes reflect areas of strategic alignment with our long-term impact goals. These outcomes are intended to illustrate the types of non-financial progress S2G seeks to support across its portfolio and do not represent company-specific metrics or outcomes. They are not a reflection of investment performance, actual or realized returns, or future financial results.
S2G North Star Interim Outcomes reflect areas of strategic alignment with our long-term impact goals. These outcomes are intended to illustrate the types of non-financial progress S2G seeks to support across its portfolio and do not represent company-specific metrics or outcomes. They are not a reflection of investment performance, actual or realized returns, or future financial results.